Drug Profile
Research programme: influenza A virus H7N9 vaccines - GlaxoSmithKline
Latest Information Update: 25 Apr 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Influenza A virus H7N9 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Influenza A virus H7N9 subtype
Most Recent Events
- 25 Apr 2023 Discontinued - Preclinical for Influenza A virus H7N9 subtype (Prevention) in United Kingdom (IM)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Influenza-A virus H7N9 subtype(Prevention) in United Kingdom (IM)
- 16 Jun 2016 GlaxoSmithKline withdraws a phase I trial for Influenza-A virus H7N9 subtype (Prevention) in Estonia and Hong Kong (NCT02177734)